Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Normann Steiner, Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Gabriele Zeck, David Nachbaur, Dominik Wolf, Nico Gagelmann, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2024-205849

Published: 2024

Journal Articles

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2024-210920

Published: 2024

Journal Articles

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Kristin Rathje, Kordelia Barbullushi, Nico Gagelmann, Anita Badbaran, Johanna Richter, Mathias Schäfersküpper, Franziska Elisabeth Marquard, Radwan Massoud, Sofia Oechsler, Evgeny Klyuchnikov, Ina Rudolph, Silke Heidenreich, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2024-207569

Published: 2024

Journal Articles

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Radwan Massoud, Margherita Ursi, Francesco Barbato, Francesco De Felice, Enrico Maffini, Marcello Roberto, Evgeny Klyuchnikov, Claudia Langebrake, Nico Gagelmann, Gabriele Zeck, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger, Francesca Bonifazi

Blood (2024) 144 (Supplement 1): 7374.

https://doi.org/10.1182/blood-2024-211102

Published: 2024

Journal Articles

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Nico Gagelmann, Marie Quarder, Anita Badbaran, Christine Wolschke, Kristin Rathje, Mathias Schäfersküpper, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Radwan Massoud, Johanna Richter, Dietlinde Janson, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 630.

https://doi.org/10.1182/blood-2023-191242

Published: 2023

Journal Articles

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis A. Ayuk, Ulrike Bacher, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2023-188998

Published: 2023

Journal Articles

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Radwan Massoud, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Anita Badbaran, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 7014.

https://doi.org/10.1182/blood-2023-188880

Published: 2023

Journal Articles

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Radwan Massoud, Evgeny Klyuchnikov, Ameya Shrinivas Kunte, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2023-188745

Published: 2023

Journal Articles

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Ameya Shrinivas Kunte, Nico Gagelmann, Anita Badbaran, Carolina Berger, Radwan Massoud, Evgeny Klyuchnikov, Christine Wolschke, Dietlinde Janson, Ulrike Fritsche-Friedland, Boris Fehse, Nicolaus Kroeger, Francis A. Ayuk

Blood (2022) 140 (Supplement 1): 7531–7532.

https://doi.org/10.1182/blood-2022-168667

Published: 2022

Journal Articles

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatjana Zabelina, Wolschke Christine, Francis Ayuketang Ayuk, Ulrike Fritsche-Friedland, Axel R. Zander, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2021-153157

Published: 2021

Journal Articles

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Maximilian Christopeit, Dietlinde Janson, Francis A. Ayuk, Christine Wolschke, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2021-152148

Published: 2021

Journal Articles

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Razan Mohty, MD, Radwan Massoud, BS, MD, Zaher Chakhachiro, MD, Rami Mahfouz, MD, Samer Nassif, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2019) 134 (Supplement_1): 3860.

https://doi.org/10.1182/blood-2019-125237

Published: 2019

Journal Articles

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Nour Moukalled, MD, Radwan Massoud, BS, MD, Rami Mahfouz, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2018) 132 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2018-99-118893

Published: 2018

Journal Articles

Interim Disease Evaluation Post Induction Chemotherapy for Acute Myeloid Leukemia

Nour Moukalled, Radwan Massoud, MD, Rami Mahfouz, MD, Zaher Chakhachiro, MD, Samer Nassif, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2017) 130 (Supplement 1): 5022.

https://doi.org/10.1182/blood.V130.Suppl_1.5022.5022

Published: 2017

Journal Articles

Consolidation with Bortezomib, Lenalidomide and Dexamethasone Upgrades the Complete Remission Rate after Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma

Iman Aboudalle, MD, Basel Haffar, MD, Radwan Massoud, MD, Ali Bazarbachi, MD PhD, Jean Elcheikh, MD

Blood (2017) 130 (Supplement 1): 1821.

https://doi.org/10.1182/blood.V130.Suppl_1.1821.1821

Published: 2017

Journal Articles

Predictorsof Early Engraftment in Autologous Peripheral Stem Cell Transplantation; a Single Center Experience

Radwan Massoud, MD, Zaher K. Otrock, MD, Rami Mahfouz, MD, Ammar Zaherddine, RN, Nabila Kreidieh, Rita Nehme, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2017) 130 (Supplement 1): 5514.

https://doi.org/10.1182/blood.V130.Suppl_1.5514.5514

Published: 2017

Journal Articles

Safety and Efficacy of Thiotepa Based Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Single Center Experience

Jean Elcheikh, MD, Radwan Massoud, MD, Nour Moukalled, Basel Haffar, MD, Ammar Zaherddine, RN, Charafeddine Maya, Rami Mahfouz, MD, Ali Bazarbachi, MD PhD

Blood (2017) 130 (Supplement 1): 5473.

https://doi.org/10.1182/blood.V130.Suppl_1.5473.5473

Published: 2017

Journal Articles

Sequential Regimen with Thiotepa, Cyclophosphamide, Etoposide, Fludarabine and Busulfan in Allogeneic Stem Cell Transplantation for the Treatment of Relapsed and Refractory Hematological Malignancies

Haidar El Darsa, Radwan Massoud, MD, Basel Haffar, MD, Ammar Zaherddine, RN, Ali Bazarbachi, MD PhD, Jean Elcheikh, MD

Blood (2017) 130 (Supplement 1): 5469.

https://doi.org/10.1182/blood.V130.Suppl_1.5469.5469

Published: 2017

Journal Articles

Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT

Jean Elcheikh, MD, Radwan Massoud, MD, Elie Fares, Mohamed A Kharfan-Dabaja, MD, Jisr Tamima, MD, Anas Mougharbel, MD, Ali Bazarbachi, MD PhD, Ahmad Ibrahim

Blood (2016) 128 (22): 5359.

https://doi.org/10.1182/blood.V128.22.5359.5359

Published: 2016

Journal Articles

Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

Rana Salem, MD, Radwan Massoud, MD, Rami Mahfouz, Ali Bazarbachi, MD PhD, Jean El Cheikh, MD PhD

Blood (2016) 128 (22): 5238.

https://doi.org/10.1182/blood.V128.22.5238.5238

Published: 2016

NARROW

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Interim Disease Evaluation Post Induction Chemotherapy for Acute Myeloid Leukemia

Consolidation with Bortezomib, Lenalidomide and Dexamethasone Upgrades the Complete Remission Rate after Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma

Predictorsof Early Engraftment in Autologous Peripheral Stem Cell Transplantation; a Single Center Experience

Safety and Efficacy of Thiotepa Based Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Single Center Experience

Sequential Regimen with Thiotepa, Cyclophosphamide, Etoposide, Fludarabine and Busulfan in Allogeneic Stem Cell Transplantation for the Treatment of Relapsed and Refractory Hematological Malignancies

Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT

Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only